This review is a summary of an individual study; 5-year overall survival with combined nivolumab and ipilimumab in advanced melanoma.
Independent commentary is provided by Dr Megan Lyle, a medical oncologist at the Liz Plummer Cancer Centre at Cairns Hospital.
Please login below to download this issue (PDF)